Two peptides can knock on the same growth-hormone door from opposite sides.
That is the real hook behind CJC-1295 vs Ipamorelin. The names sound like competitors, but their biology makes them a natural comparison pair.
CJC-1295 uses the GHRH pathway; ipamorelin uses the ghrelin receptor pathway, so researchers often compare them or study them together.
If you remember only one thing, remember this: they aim at the same broad research conversation through different receptor systems.
CJC-1295 vs Ipamorelin at a glance
| Question | CJC-1295 | Ipamorelin |
|---|---|---|
| What is it? | A GHRH analog | A five-amino-acid GH secretagogue |
| Main pathway | GHRH receptor | Ghrelin receptor, also called GHS-R |
| Main research idea | Extend or model GHRH signaling | Trigger a selective GH-release signal |
| Available alone? | Yes | Yes |
| Available together? | Yes, using CJC-1295 without DAC | Yes, in the same fixed blend |
Think of the pituitary as a control room. CJC-1295 sends a message modeled after the body’s growth-hormone-releasing hormone. Ipamorelin sends a different message through a receptor better known for responding to ghrelin.
Different buttons. Related output.
What does CJC-1295 do?
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone, usually shortened to GHRH. GHRH is one of the body’s natural signals for telling the pituitary to release growth hormone.
There are two important product names:
- CJC-1295 without DAC, also called Mod GRF 1-29, is the non-DAC reference.
- CJC-1295 with DAC includes a Drug Affinity Complex designed to extend its time in circulation.
That distinction matters. A published healthy-adult study of the DAC-modified form reported prolonged, dose-dependent increases in growth hormone and IGF-1. The researchers estimated a half-life of 5.8 to 8.1 days. Read the CJC-1295 human study on PubMed.
The result made long-acting GHRH signaling the headline for CJC-1295 with DAC. The no-DAC form supports a different laboratory design when researchers want the GHRH analog without that extension technology.
What makes Ipamorelin different?
Ipamorelin is a pentapeptide, meaning it contains five amino acids. It belongs to the growth-hormone-secretagogue family and acts through a GHRP-like receptor now known as the ghrelin receptor, or GHS-R.
The original pharmacology paper described Ipamorelin as a selective growth-hormone secretagogue. In the reported animal models, it produced a strong GH-release signal without the same significant ACTH or cortisol release seen with two comparison GHRPs. Read the Ipamorelin selectivity paper on PubMed.
That is why “selective” stays close to the Ipamorelin name. It gives researchers a cleaner way to frame GH-secretagogue pathway studies.
Which is better: CJC-1295 or Ipamorelin?
Neither is automatically better. The better reference is the one that answers the study question.
- Choose CJC-1295 without DAC for a non-DAC GHRH-analog reference.
- Choose CJC-1295 with DAC for long-acting, DAC-focused GHRH research.
- Choose Ipamorelin for a selective GHS-R secretagogue reference.
- Choose the CJC-1295 + Ipamorelin blend for a fixed, dual-pathway comparison material.
Separate vials give a laboratory control over each peptide. A fixed blend makes repeat purchasing and single-agent-versus-combination comparisons easier.
Why is CJC-1295 paired with Ipamorelin?
The pairing is easy to understand once you see the two pathways.
CJC-1295 copies the direction of the GHRH message. Ipamorelin uses the ghrelin-receptor route. Studying them together lets a researcher examine two inputs connected to GH release without pretending the peptides are identical.
For the same two receptor families with a different GHRH analog, compare Tesamorelin vs Ipamorelin.
Certiva’s fixed blend uses CJC-1295 without DAC, not the DAC form. Each vial contains:
- 5 mg CJC-1295 without DAC;
- 5 mg Ipamorelin; and
- 10 mg total peptide material.
Standard boxes contain 10 vials.
What vial sizes can I order?
Certiva’s stocked research formats include:
- CJC-1295 without DAC: 5 mg and 10 mg per vial;
- CJC-1295 with DAC: 2 mg, 5 mg, and 10 mg per vial;
- Ipamorelin: 5 mg and 10 mg per vial; and
- CJC-1295 without DAC + Ipamorelin: 5 mg + 5 mg per vial.
Bulk quantities and custom requests are available by inquiry. Every order should be matched to the exact peptide name, vial strength, lot, and documentation.
What should I check before buying?
A comparison article can explain biology. It cannot verify the powder in a vial. For that, ask for the batch documents.
Check:
- whether the CJC-1295 is with DAC or without DAC;
- the exact amount of each peptide in the vial;
- the lot number on the vial and report;
- the HPLC purity result;
- the identity test; and
- storage, lead time, and shipping details.
Use our plain-English guide on how to read a peptide COA before placing a research order.
Choose the pathway that matches the study
CJC-1295 is the GHRH-side of the comparison. Ipamorelin is the ghrelin-receptor side.
Choose a single peptide when one pathway is the point of the study. Choose the fixed no-DAC blend when the project needs both references in one documented composition.
Certiva supplies these materials strictly for laboratory research use only, not for human consumption.
Compare the current COAs
Tell us which format you need, the vial strength, box quantity, destination country, and documentation requirements. We will reply with availability, applicable batch information, lead time, and a quote.
Compare CJC-1295 and Ipamorelin COAs →
Sources and further reading
- PubMed: prolonged GH and IGF-1 signaling after CJC-1295 with DAC
- PubMed: Ipamorelin as a selective growth-hormone secretagogue
Frequently asked questions
What is the main difference between CJC-1295 and Ipamorelin?
CJC-1295 uses the GHRH pathway; ipamorelin uses the ghrelin receptor pathway, so researchers often compare them or study them together.
Is CJC-1295 the same as Ipamorelin?
No. CJC-1295 is a GHRH analog, while Ipamorelin is a five-amino-acid growth-hormone secretagogue that acts through the ghrelin, or GHS-R, pathway.
Why are CJC-1295 and Ipamorelin studied together?
They are studied together because they approach growth-hormone release through different receptor pathways. This makes the pair useful for single-agent versus dual-pathway laboratory comparisons.
Does the Certiva CJC-1295 and Ipamorelin blend contain DAC?
No. The Certiva blend contains 5 mg CJC-1295 without DAC plus 5 mg Ipamorelin in each vial, for 10 mg total.
Can I order CJC-1295 and Ipamorelin separately?
Yes. Certiva supplies CJC-1295 without DAC, CJC-1295 with DAC, Ipamorelin, and a fixed CJC-1295 without DAC plus Ipamorelin blend for laboratory research.
For research use only. Not for human consumption. This article is educational and makes no medical, therapeutic, or dosing claims.
← More sourcing & supply guides · Have a question? Start an inquiry →